Soleno Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Soleno Therapeutics kazanç ve gelirinin sırasıyla yıllık 67.3% ve 66.6% oranında artması tahmin edilirken, EPS'nin yıllık 66.2% oranında büyümesi bekleniyor.

Anahtar bilgiler

67.3%

Kazanç büyüme oranı

66.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.6%
Gelir büyüme oranı	66.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	18 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Nov 08

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 10

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Mar 08

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Sep 20

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Aug 26

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Aug 12

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Jul 20

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

May 10

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Jan 24

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Jun 02

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Mar 23

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Jan 29

Soleno Therapeutics: Could Be Big Fish In The Small Pond

Jan 08

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:SLNO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	151	-33	-1	-46	6
12/31/2025	37	-115	-49	-78	8
12/31/2024	N/A	-163	-304	-67	8
9/30/2024	N/A	-131	-52	-51	N/A
6/30/2024	N/A	-65	-43	-43	N/A
3/31/2024	N/A	-52	-31	-31	N/A
12/31/2023	N/A	-39	-25	-25	N/A
9/30/2023	N/A	-33	-24	-24	N/A
6/30/2023	N/A	-28	-22	-22	N/A
3/31/2023	N/A	-27	-21	-21	N/A
12/31/2022	N/A	-24	-21	-21	N/A
9/30/2022	N/A	-21	-23	-23	N/A
6/30/2022	N/A	-23	-23	-23	N/A
3/31/2022	N/A	-28	-27	-27	N/A
12/31/2021	N/A	-31	-28	-28	N/A
9/30/2021	N/A	-31	-28	-28	N/A
6/30/2021	N/A	-31	-29	-29	N/A
3/31/2021	N/A	-28	-27	-27	N/A
12/31/2020	N/A	-25	-25	-25	N/A
9/30/2020	N/A	-36	-23	-23	N/A
6/30/2020	N/A	-27	-22	-22	N/A
3/31/2020	N/A	-30	-19	-19	N/A
12/31/2019	N/A	-31	-17	-17	N/A
9/30/2019	N/A	-16	-16	-16	N/A
6/30/2019	N/A	-19	-14	-14	N/A
3/31/2019	N/A	-16	-13	-13	N/A
12/31/2018	N/A	-12	-12	-12	N/A
9/30/2018	N/A	-16	-11	-11	N/A
6/30/2018	N/A	-17	N/A	-10	N/A
3/31/2018	N/A	-13	N/A	-10	N/A
12/31/2017	N/A	-12	N/A	-10	N/A
9/30/2017	N/A	-13	N/A	-10	N/A
6/30/2017	0	-11	N/A	-11	N/A
3/31/2017	0	-9	N/A	-12	N/A
12/31/2016	N/A	-10	N/A	-13	N/A
9/30/2016	0	-8	N/A	-14	N/A
6/30/2016	0	-10	N/A	-14	N/A
3/31/2016	1	-7	N/A	-12	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	0	-20	N/A	-8	N/A
6/30/2015	0	-19	N/A	-7	N/A
3/31/2015	0	-24	N/A	-6	N/A
12/31/2014	N/A	-13	N/A	-4	N/A
9/30/2014	N/A	-7	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-3	N/A
3/31/2014	N/A	-6	N/A	-3	N/A
12/31/2013	3	-4	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SLNO önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: SLNO önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: SLNO önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: SLNO şirketinin gelirinin (yıllık 66.6% ) US pazarından (yıllık 9.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SLNO şirketinin gelirinin (yıllık 66.6% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SLNO 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 20:25
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Soleno Therapeutics, Inc. 12 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
Kristen Kluska	Cantor Fitzgerald & Co.
François Brisebois	Craig-Hallum Capital Group LLC

Soleno Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2026

Price target increased by 8.0% to US$73.57

No longer forecast to breakeven

Price target increased by 19% to US$60.17

Forecast to breakeven in 2026

Price target increased by 23% to US$45.67

Recent updates

Soleno Therapeutics, Inc. announced that it expects to receive $200 million in funding

Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Forecast to breakeven in 2026

Price target increased by 8.0% to US$73.57

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

President recently sold US$1.1m worth of stock

President recently sold US$5.5m worth of stock

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

No longer forecast to breakeven

President recently sold US$5.8m worth of stock

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

President recently sold US$800k worth of stock

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Independent Chairman exercised options to buy US$2.6m worth of stock.

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

President recently sold US$785k worth of stock

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Price target increased by 19% to US$60.17

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Forecast to breakeven in 2026

Vice President of Clinical Operations notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

President recently sold US$1.5m worth of stock

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Price target increased by 23% to US$45.67

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

New major risk - Shareholder dilution

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

New major risk - Financial position

No longer forecast to breakeven

No longer forecast to breakeven

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Forecast to breakeven in 2025

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Price target decreased to US$9.00

Insufficient new directors

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Insufficient new directors

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Insufficient new directors

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Price target decreased to US$5.00

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Price target lowered to US$7.00

New 90-day low: US$1.38